Skip to main content
SpringerLink
Log in

Eltrombopag: A Review of Its Use in Patients with Severe Aplastic Anaemia

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Eltrombopag (Promacta®) is an orally active thrombopoietin receptor agonist recently approved in the US for the treatment of patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy. This article reviews the efficacy and tolerability of eltrombopag in this indication and overviews its pharmacological properties. Eltrombopag does not compete with thrombopoietin and binds to a different site on the receptor, producing additive effects. It stimulates haematopoietic stem cells and promotes haematopoietic recovery in patients with aplastic bone marrow. Eltrombopag increased platelet counts and can also increase red blood cell and neutrophil counts. In patients with severe aplastic anaemia refractory to prior immunosuppressive therapy, oral eltrombopag at dosages ≤150 mg once daily for 12–16 weeks produced a haematological response in at least one cell lineage in 40 % of patients. Trilineage responses were achieved in nearly one-half of the responders during extended treatment. In robust responders, stable haematological counts were maintained after eltrombopag discontinuation. Eltrombopag was generally well tolerated, with increased liver transaminases as the only dose-limiting toxicity. Clonal cytogenetic abnormalities were observed in 19 % of patients and dysplasia in 5 % of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Marsh JCW, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43–70.

    Article  CAS  PubMed  Google Scholar 

  2. Dezern AE, Brodsky RA. Clinical management of aplastic anemia. Expert Rev Hematol. 2011;4(2):221–30.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Scheinberg P. Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematology Am Soc Hematol Educ Program. 2012;2012:292–300.

    PubMed  Google Scholar 

  4. Scheinberg P, Nunez O, Weinstein B, et al. A randomized trial of horse versus rabbit antithymocyte globulin in severe acquired aplastic anemia. N Engl J Med. 2011;365(5):430–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185–96.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Marsh JCW, Mufti GJ. Eltrombopag: a stem cell cookie? Blood. 2014;123(12):1774–5.

    Article  CAS  PubMed  Google Scholar 

  7. Marsh JCW, Ganser A, Stadler M. Hematopoietic growth factors in the treatment of acquired bone marrow failure states. Semin Hematol. 2007;44(3):138–47.

    Article  CAS  PubMed  Google Scholar 

  8. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367(1):11–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. US FDA. Promacta (eltrombopag) tablets: US prescribing information. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022291s012lbl.pdf. Accessed 12 Feb 2015.

  10. Garnock-Jones KP. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia. Drugs. 2011;71(10):1333–53.

    Article  CAS  PubMed  Google Scholar 

  11. Burness CB. Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis C. Drugs. 2014;74(16):1961–71.

    Article  CAS  PubMed  Google Scholar 

  12. Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009;27(2):424–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Sun H, Tsai Y, Nowak I, et al. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res. 2012;9(2):77–86.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109(11):4739–41.

    Article  CAS  PubMed  Google Scholar 

  15. Shida Y, Takahashi N, Nohda S, et al. Pharmacokinetics and pharmacodynamics of eltrombopag in healthy Japanese males. Jpn J Clin Pharmacol Ther. 2011;42(1):11–20.

    Article  CAS  Google Scholar 

  16. Erhardt JA, Erickson-Miller CL, Aivado M, et al. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol. 2009;37(9):1030–7.

    Article  CAS  PubMed  Google Scholar 

  17. Matthys G, Park JW, McGuire S, et al. Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects. Br J Clin Pharmacol. 2010;70(1):24–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Matthys G, Park JW, McGuire S, et al. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers. J Clin Pharmacol. 2011;51(3):301–8.

    Article  CAS  PubMed  Google Scholar 

  19. Gibiansky E, Zhang J, Williams D, et al. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2011;51(6):842–56.

    Article  CAS  PubMed  Google Scholar 

  20. Farrell C, Hayes SC, Wire M, et al. Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease. Br J Clin Pharmacol. 2014;77(3):532–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Hayes S, Mudd PN Jr, Ouellet D, et al. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia. Cancer Chemother Pharmacol. 2013;71(6):1507–20.

    Article  CAS  PubMed  Google Scholar 

  22. Hayes S, Ouellet D, Zhang J, et al. Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing. J Clin Pharmacol. 2011;51(10):1403–17.

    Article  CAS  PubMed  Google Scholar 

  23. Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009;31(4):764–76.

    Article  CAS  PubMed  Google Scholar 

  24. Wire MB, Bruce J, Gauvin J, et al. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS. Clin Ther. 2012;34(3):699–709.

    Article  CAS  PubMed  Google Scholar 

  25. Deng Y, Madatian A, Wire MB, et al. Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects. Drug Metab Dispos. 2011;39(9):1734–46.

    Article  CAS  PubMed  Google Scholar 

  26. Bauman JW, Vincent CT, Peng B, et al. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics. J Clin Pharmacol. 2011;51(5):739–50.

    Article  CAS  PubMed  Google Scholar 

  27. Jenkins J, Williams D, Deng Y, et al. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis. Eur J Clin Pharmacol. 2010;66(1):67–76.

    Article  CAS  PubMed  Google Scholar 

  28. Allred AJ, Bowen CJ, Park JW, et al. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. Br J Clin Pharmacol. 2011;72(2):321–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818–25.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Kuter DJ, Mufti GJ, Bain BJ, et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009;114(18):3748–56.

    Article  CAS  PubMed  Google Scholar 

  31. Maciejewski JP, Selleri C. Evolution of clonal cytogenetic abnormalities in aplastic anemia. Leuk Lymphoma. 2004;45(3):433–40.

    Article  PubMed  Google Scholar 

  32. Marsh JCW, Kulasekararaj AG. Management of the refractory aplastic anemia patient: what are the options? Hematology Am Soc Hematol Educ Program. 2013;2013:87–94.

    Article  PubMed  Google Scholar 

  33. Desmond R, Townsley DM, Dunbar C, et al. Eltrombopag in aplastic anaemia. Semin Hematol. 2014 (in press). doi:10.1053/j.seminhematol.2014.10.002.

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit. Paul L. McCormack is a salaried employee of Adis/Springer.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand

    Paul L. McCormack

Authors
  1. Paul L. McCormack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul L. McCormack.

Additional information

The manuscript was reviewed by: M. J. Olnes, Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA; P. Scheinberg, Clinical Hematology, Antonio Ermírio de Moraes Cancer Center, Hospital São José and Beneficência Portuguesa, Sao Pãulo, Brazil.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McCormack, P.L. Eltrombopag: A Review of Its Use in Patients with Severe Aplastic Anaemia. Drugs 75, 525–531 (2015). https://doi.org/10.1007/s40265-015-0363-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0363-4

Keywords

Search

Navigation